Kronos Bio Announces Participation in 35th Annual Piper Sandler Healthcare Conference
27 Novembre 2023 - 10:05PM
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to
transforming the lives of those affected by cancer, today announced
that Norbert Bischofberger, Ph.D., president and chief executive
officer, Jorge DiMartino M.D., Ph.D., chief medical officer and
executive vice president of clinical development, and Charles Lin,
Ph.D., senior vice president of TRN Mapping will participate in a
fireside chat at the 35th Annual Piper Sandler Healthcare
Conference on Tuesday, November 28, 2023 at 4:00 p.m. ET.
A live audio webcast of the event will be
available on the Investors and Media section of the Kronos Bio
website at www.kronosbio.com. A replay of the webcast will be
available for 30 days following the event.
About Kronos Bio, Inc.
Kronos Bio is a biopharmaceutical company that
is advancing two investigational compounds in clinical trials for
patients with cancer. The Company is developing the CDK9 inhibitor
KB-0742 as a treatment for MYC-amplified solid tumors and other
transcriptionally addicted solid tumors and lanraplenib, a
next-generation SYK inhibitor, for patients with FLT3-mutated acute
myeloid leukemia. The Company’s scientific focus is on developing
medicines that target the deregulated transcription that is the
hallmark of cancer and other serious diseases.
Kronos Bio is based in San Mateo, Calif., and
has a research facility in Cambridge, Mass. For more information,
visit https://www.kronosbio.com/ or follow the Company on
LinkedIn.
Media Contact:Sarah ConnorsVice President of
Corporate Affairs, Kronos Bio857-290-7305sconnors@kronosbio.com
Investor Contact:Margaux BennettExecutive
Director, Business Development and Investor Relations, Kronos
Bio650-781-5026mbennett@kronosbio.com
Grafico Azioni Kronos Bio (NASDAQ:KRON)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Kronos Bio (NASDAQ:KRON)
Storico
Da Mag 2023 a Mag 2024